Alpha-Blocker Treatment Response in Men With Lower Urinary Tract Symptoms Based on Sympathetic Activity: Prospective, Multicenter, Open-Labeled, Observational Study
- Authors
- Park, Sung Gon; Chung, Byung Ha; Lee, Sung Won; Park, Jong Kwan; Park, Kwangsung; Cheon, Jun; Lee, Kyung Seop; Kim, Hyung-Jee; Seong, Do-Hwan; Oh, Seung-June; Kim, Sae Woong; Lee, Ji Youl; Choo, Seol Ho; Choi, Jong Bo
- Issue Date
- 6월-2015
- Publisher
- KOREAN CONTINENCE SOC
- Keywords
- Heart Rate; Prostatic Hyperplasia; Sympathetic Nervous System; Lower Urinary Tract Symptoms
- Citation
- INTERNATIONAL NEUROUROLOGY JOURNAL, v.19, no.2, pp.107 - 112
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- INTERNATIONAL NEUROUROLOGY JOURNAL
- Volume
- 19
- Number
- 2
- Start Page
- 107
- End Page
- 112
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/93327
- DOI
- 10.5213/inj.2015.19.2.107
- ISSN
- 2093-4777
- Abstract
- Purpose: In this study, we compared the treatment outcomes for an a-blocker between 2 groups of men, one with high sympathetic activity (HSA) and another with low sympathetic activity (LSA) or normal sympathetic activity. Methods: A total of 159 men (>= 50 years of age) with lower urinary tract symptoms resulting from benign prostatic hyperplasia were analyzed. We assigned patients to groups according to their sympathetic activity, which was evaluated by heart rate variability measurements. HSA was defined as a low frequency/high frequency ratio greater than 1.6. All patients received 10 mg of alfuzosin once a day for 12 weeks. The primary end point was a change in the total International Prostate Symptom Score (IPSS) at 12 weeks from baseline. Results: Sixty-seven men were assigned to the HSA group and 92 men were assigned to the LSA group. The baseline characteristics were not significantly different between the 2 groups, and the response to alfuzosin was good in both groups. The mean total IPSS change was not different between the groups. Both groups were not significantly different with respect to the changes in maximal flow rate, IPSS voiding or storage symptom subscores, quality of life, and rates of adverse drug events. The HSA group showed a similar willingness to continue treatment compared to the LSA group, although their treatment satisfaction rating was lower. Conclusions: The therapeutic effects of alfuzosin did not differ in regards to the differences in sympathetic activity, but treatment satisfaction ratings were lower in the HSA group.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.